Navigation Links
Breast Cancer Tends to Grow Faster in Younger Women
Date:5/8/2008

Finding could affect how screenings are conducted, analyzed, researchers say

THURSDAY, May 8 (HealthDay News) -- While the rate at which breast cancer tumors grow varies among patients, that growth tends to be faster among younger women, Norwegian researchers report.

These findings may help in planning and evaluating screening programs, clinical trials and other studies, the researchers say.

Using a new mathematical model, the scientists were also able to estimate the numbers of breast cancers detectable by mammography. This is a new approach to estimating the growth rate of tumors and the ability of mammograms to find them.

"There are enormous implications for the sensitivity of breast cancer screening programs," lead researcher Harald Weedon-Fekjr, of the Department of Etiological Research, Cancer Registry of Norway, said in a statement.

"We found that mammography screen test sensitivity increases sharply with increased tumor size, as one might expect. Detection rates are just 26 percent for a 5 millimeter tumor but increase to 91 percent once a tumor is 10 millimeter in size," he added.

The report was published in the May 8 issue of the online journal Breast Cancer Research.

In the study, Weedon-Fekjr, and colleagues tested their model using mammography results from 395,188 women aged 50 to 69.

The researchers found that the growth rate of tumors varied significantly between patients. About one in 20 tumors doubled in size, from 10 to 20 millimeters in just over a month. However, a similar number of tumors took more than six years to double in size.

Based on this finding, Weedon-Fekjr's team estimated that it takes an average of 1.7 years for tumors to double in size. Moreover, tumor growth appeared to be faster among younger women and slowed as women aged, the researchers noted.

"Tumor growth and test sensitivity estimates can be directly linke
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Cancer Tends to Grow Faster in Younger Women
Breast Cancer Tends to Grow Faster in Younger Women
(Date:12/4/2008)...suggests more choices need to be available to coup...s) -- A new survey suggests that many American wom...appy with the usual options available for the disp..., Most of 1,020 women surveyed said they were ver...o be thawed and thrown away, used by other women, ...
(Date:12/4/2008)...ogists have discovered a mechanism that is critica..., where a cell divides into two identical daughter...ow on the assembly and activity of a ring of actin...l at just the right time. They focused on key prot...romote the production of both linear and branching...
(Date:12/4/2008)...GELES, Dec. 4 Jessica Biel and fam...liday party held Dec. 2 at the Childrens,Hospital...ake The Difference,Network, included numerous rec...n an effort to bring holiday spirit to children at...umerous activities as well as seeing some of the,...
(Date:12/4/2008)...GTON, Dec. 4 On this I...gainst Women , the Pan American Health and Educati...s Global Violence Prevention project. The project ...mmunity that violence is preventable. , , ...nce Prevention: The Investment that Saves Lives , ...
Breaking Medicine News(10 mins):Health News:Women Unhappy With Disposal Options After Infertility Treatment 2Health News:Women Unhappy With Disposal Options After Infertility Treatment 3Health News:Researchers gain new insight on wonder of cell division 2Health News:Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles 2Health News:PAHEF Works to Prevent Violence Against Women 2
... debt ridden NHS hospital's radiotherapy departmen...sm from the union and the conservatives//. To eff...in Suffolk, suggestions came in from the staff tha...n Saturdays to put the under utilized equipments t...
... pride of people of the Ottawa region when the cla...Health Centre which offers// psychiatric care and...,000-square-foot facility puts 188 inpatient beds ...ng the first public hospital to be entirely financ...
...scious in Jaipur, flower therapy is becoming the m...ng people enhance their beauty are parlours// and ...cne problems or under eye dark circles, flower the...on. "We get 7 to 10 customers every day," says Ne...
...e on patients to unravel the effect of behavioral...st a couple of sessions of counseling// that focus...to find themselves sleeping well. During sessions...reasons which could cause sleeplessness in individ...
Other Medicine News:Health News:Pet Peeves: Conservatives Howl at Proposal to Share NHS Hosp by Pets and People 2
(Date:12/4/2008)...PRNewswire-FirstCall/ -- Thoratec Corporation,(Na...hanical circulatory support,therapies to save, su...a,pre-specified interim analysis of data from its...ial shows that patients implanted with the device,...hose in the control group who,were implanted with...
(Date:12/4/2008)... to Advance to Clinical Trials , , SAN DIEG... Inc., a biopharmaceutical company focused on the ...gonists for the treatment of cancer, respiratory a...s initiated a Phase I clinical trial of VTX-2337, ...er. The multi-center clinical trial is being cond...
(Date:12/3/2008)...monstrating potential in newly diagnosed patients ...tured in two oral sessions at ASH , , - Exj...y transfused patients by significantly reducing to...ew long-term data from major independent breast ca...ery treatment strategy, Femara vs. tamoxifen , ...
(Date:12/3/2008)...iates long-term anemia and organ damage in mice an... MEMPHIS, Tenn., Dec. 3 ...e into mouse blood cells, scientists at St. Jude C... cell disease pathology. In their studies, the res...ially no difference from normal mice. Although the...
Breaking Medicine Technology:Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 2Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 3Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 4VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform 3091 1AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform 3091 2AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform 3091 3A breakthrough in contrast enhanced intraoperative ultrasonography 26539 1Does probiotic intervention induce the serum global lipid profile change 3F 26535 1Does probiotic intervention induce the serum global lipid profile change 3F 26535 2Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday September 24th 3090 1Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday September 24th 3090 2
...alif.--(BUSINESS WIRE)--Mar 22, 2007 - Aeolus,Phar... successful,completion of the analysis of results ...AEOL 10150 ("Study 102"). The clinical,direction f...th the,most likely targets for an efficacy study a...y in lung cancer and/or head and neck,cancer and A...
...--(BUSINESS WIRE)--Mar 22, 2007 - Nutra Pharma,Cor...developing,drugs for HIV and Multiple Sclerosis ha..., ReceptoPharm, has received notification of,accep... Reviews in,Immunology special conference issue., ...ble therapy,for Multiple Sclerosis; a review of th...
Other Medicine Technology:Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150 2Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150 3Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
Performa cemented stem.
Porous foundation 470 series.
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications.
The link classic plus hip stem for cemented primary hip replacement surgery
Medicine Products: